FindMyRecallSubscribe
Class I: serious health riskTerminated

Mylan Pharmaceuticals Semglee Recall

Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 495…

Mylan Pharmaceuticals Inc · Morgantown, WV

Risk level
Class I
Reported by FDA
Jan 26, 2022
Recall ID
D-0462-2022
Check your lot numberHow we source this data

Summary

Mylan Pharmaceuticals recalled Semglee starting Jan 5, 2022. The FDA classified it as Class I (serious health risk) and published enforcement report D-0462-2022 on Jan 26, 2022. Reason: Labeling: Missing Label: label missing from some Semglee prefilled pens. Status: Terminated.

Why it was recalled

Labeling: Missing Label: label missing from some Semglee prefilled pens.

Product description

Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 49502-0196-71), packaged in Five 3 mL Prefilled Pens per carton (NDC 49502-0196-75), Rx only, Manufactured in Malaysia for: Mylan Specialty L.P., Morgantown, WV, 26505.

Lot numbers, UPCs & expiration codes

Batch # BF20003118, Exp. August 2022

Where it was sold

Nationwide in the USA and Thailand.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0462-2022
Classification
Class I
Status
Terminated
Recall initiated
Jan 5, 2022
FDA report date
Jan 26, 2022
Quantity
73,175 prefilled pens
Recall type
Voluntary: Firm initiated
Recalling firm
Mylan Pharmaceuticals Inc

Original FDA data

Every field from FDA enforcement report D-0462-2022, exactly as published.

Show all FDA fields
City
Morgantown
State
WV
Status
Terminated
Country
United States
Event ID
89357
Address
3711 Collins Ferry Rd
Code information
Batch # BF20003118, Exp. August 2022
Postal code
26505-2362
Report date
Jan 26, 2022
Product type
Drugs
Recall number
D-0462-2022
Classification
Class I
Recalling firm
Mylan Pharmaceuticals Inc
Product quantity
73,175 prefilled pens
Termination date
Jan 12, 2024
Reason for recall
Labeling: Missing Label: label missing from some Semglee prefilled pens.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 49502-0196-71), packaged in Five 3 mL Prefilled Pens per carton (NDC 49502-0196-75), Rx only, Manufactured in Malaysia for: Mylan Specialty L.P., Morgantown, WV, 26505.
Distribution pattern
Nationwide in the USA and Thailand.
Recall initiation date
Jan 5, 2022
Initial firm notification
Letter
Center classification date
Jan 28, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0462-2022, published Jan 26, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls